Am I correct in thinking that there is no further

Am I correct in thinking that there is no further need for Dr. M's attention to the current 3 drugs in the IPIX arsenal as they can work across the many indications that have been mentioned in their PR's simply by varying the formulation for the required delivery system? I am assuming delivery formulation is something that can be done by skilled scientists and wouldn't require a chemical/biological visionary to get accomplished. It also means that should IPIX sell/partner/license a drug platform to a specific BP that there should be no problems for the BP to do the same. In fact, they should be able to do it faster and easier with their vastly greater resources in doctors, equipment, money, and other resources.

If above correct, Dr M could be working on new products or tweaking some of those obtained in the Poly deal as he did Brilacidin. Of course, he already had other drugs he has been working on for years (such as the autism drug) and maybe he is perfecting those.

Bottom line is that Dr M does his own thing in the lab and Dr B and Leo steer our current products through the pathways of clinical trials.

I personally don't see much to gain from the Jan 8 SF mtg. I imagine those BP's w/ CDA's have a vast head start over any newbie showing up in SF.